Make Informed Investment Decisions with Affordable Access to Experts
Understanding Tumor Infiltrating Lymphocytes (TIL) therapy currently being developed by IovanceTicker(s): IOVA
Name: Dr Tobias Schatton - PHD
- Assistant Professor of Dermatology at Harvard Medical School, a Research Associate at the Department of Dermatology at Brigham and Women’s Hospital and the Department of Medicine at Boston Children’s Hospital, and Affiliated Faculty Faculty Member of the Harvard Stem Cell Institute.
- Laboratory research centers on immune checkpoint pathways in melanoma and other skin cancers.
- Study focuses on previously unrecognized skin- and cancer cell-intrinsic vs. tumor-infiltrating lymphocyte (TIL)-specific roles of the PD-1:PD-1 ligand and Tim-3:Gal-9 axes in tumor immune evasion and cancer progression.
Please describe your clinical practice as it relates to cancer immunotherapies.Added By: c_admin
Can you briefly explain TIL as a mechanism of action?Added By: c_admin
What are your thoughts on Tumor Infiltrating Lymphocytes (TIL) therapy currently being developed by Iovance?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.